

B'SYS GmbH

# HEK Ca<sub>v</sub>3.2 Cell Line

Specification Sheet

© B'SYS GmbH

---

## TABLE OF CONTENTS

<b>1</b>	<b>BACKGROUND</b> .....	<b>3</b>
1.1	B'SYS's HEK Ca <sub>v</sub> 3.2 Cells .....	3
<b>2</b>	<b>PRODUCT SHIPMENT</b> .....	<b>3</b>
2.1	Product Format.....	3
2.2	Mycoplasma Certificate.....	3
<b>3</b>	<b>VALIDATION OF HEK CA<sub>v</sub>3.2 CELLS</b> .....	<b>3</b>
3.1	Electrophysiology .....	3
3.2	Positive Control Mibefradil.....	4
3.3	Patch-clamp Success Rates.....	4
<b>4</b>	<b>CELL CULTURE CONDITIONS</b> .....	<b>5</b>
4.1	General .....	5
4.2	Recommended Complete Medium.....	5
4.3	Antibiotics .....	5
4.4	Thawing Cells .....	5
4.5	Splitting Cells .....	5
4.6	Freezing Medium .....	6
4.7	Freezing Cells .....	6
<b>5</b>	<b>CA<sub>v</sub>3.2 SEQUENCE</b> .....	<b>7</b>
5.1	Ca <sub>v</sub> 3.2.....	7
<b>6</b>	<b>CONTACT INFORMATION</b> .....	<b>8</b>
6.1	Contact Address for Technical Support & Ordering Information .....	8

## 1 BACKGROUND

### 1.1 B'SYS's HEK Ca<sub>v</sub>3.2 Cells

B'SYS has designed a HEK Ca<sub>v</sub>3.2 cell line. The human Ca<sub>v</sub>3.2 cDNA was cloned and transfected into HEK cells and then the functional properties of the Ca<sub>v</sub>3.2 channels validated by means of the patch-clamp technique. Results are outlined in section 3.

## 2 PRODUCT SHIPMENT

### 2.1 Product Format

HEK cells stably transfected with recombinant human Ca<sub>v</sub>3.2 channel:

- 2 x 0.5 mL aliquots of frozen cells at approximately 1.0 - 3.0 E+06 cells/mL
- Cells are frozen in complete medium with 10% DMSO

### 2.2 Mycoplasma Certificate

B'SYS periodically tests cells for presence of mycoplasma by means of highly sensitive PCR based assays. All delivered cells are free of mycoplasma.

## 3 VALIDATION OF HEK CA<sub>v</sub>3.2 CELLS

### 3.1 Electrophysiology

Ca<sub>v</sub>3.2 currents were measured by means of the patch-clamp technique in the whole-cell configuration. The bath solution contained (in mM) NaCl 137, KCl 4, CaCl<sub>2</sub> 1.8, MgCl<sub>2</sub> 1, D-glucose 10, HEPES 10, pH (NaOH) 7.40. The pipette solution consisted of (in mM) KCl 130, MgCl<sub>2</sub> 1, MgATP 5, HEPES 10, EGTA 5, pH (KOH) 7.20. After formation of a GΩ seal between the patch electrodes and individual Ca<sub>v</sub>3.2 stably transfected HEK cells, the cell membrane across the pipette tip was ruptured to assure electrical access to the cell interior. All solutions applied to cells were continuously perfused and maintained at room temperature. As soon as a stable seal could be established inward calcium currents were measured upon depolarization of the cell membrane from a holding potential of -80 mV to +60 mV in 10 mV increments of 50 ms duration (Fig. 1). The voltage pulses were run at intervals of 10 s.




Fig.1: Representative current recording and IV curve of Ca<sub>v</sub>3.2 currents upon depolarization of the cell membrane from holding potential (-80 mV) up to +60 mV in 10 mV increments. No inward calcium currents were recorded in untransfected cells (data not shown).

### 3.2 Positive Control Mibefradil

Mibefradil, which is known as a T-Type Ca<sub>v</sub> blocker, was used as positive control to validate the pharmacological profile of the HEK Ca<sub>v</sub>3.2 cells. The effect of Mibefradil was first measured at 10 μM, which blocked Ca<sub>v</sub>3.2 currents almost completely ( $9.1 \pm 2.3$  % relative current amplitude, mean  $\pm$  SEM of 5 cells). When the cells were exposed to 0.01, 0.1, 1.0 and 10 μM Mibefradil, the steady-state level relative current amplitudes revealed values of  $84.7 \pm 3.2\%$ ,  $57.3 \pm 4.0\%$ ,  $19.1 \pm 2.6$  and  $9.1 \pm 2.3\%$ , respectively (mean  $\pm$  SEM of 3 cells). The inhibition curve (Fig. 2) was best fitted with an IC<sub>50</sub> value of **143.7 nM**.




Fig. 2: Ca<sub>v</sub>3.2 current inhibition curve of Mibefradil.

### 3.3 Patch-clamp Success Rates

The patch-clamp properties of the HEK Ca<sub>v</sub>3.2 cell line were elucidated at typical working passage numbers. A total of 17 cells were analyzed. Success for establishment of on-cell configuration was defined as follows: > 1 GΩ. The whole-cell configuration was not accepted if the membrane resistance was below 1 GΩ. A successful recording had to be free of rundown effects and variations in series resistance.

- On-cell successful: **91%** (n=17)
- Whole-cell successful: **82%** (n=17)
- Recording successful: **73%** (n=17)

## 4 CELL CULTURE CONDITIONS

### 4.1 General

HEK Ca<sub>v</sub>3.2 cells are incubated at 37°C in a humidified atmosphere with 5% CO<sub>2</sub> (rel. humidity > 95%). The cells are continuously maintained and passaged in sterile culture flasks containing DMEM/F12 medium supplemented with 10% fetal bovine serum, 1.0% Penicillin/Streptomycin solution and 100 µg/mL G-418. The HEK Ca<sub>v</sub>3.2 cells are passaged at a confluence of about 50-80%. For electrophysiological measurements the cells are seeded onto e.g. 35 mm sterile culture dishes containing complete medium.

- All solutions and equipment coming in contact with the cells must be sterile.
- Use proper sterile technique and work in a laminar flow hood.
- Be sure to have frozen cell stocks at hand before starting experiments.
- Cells should be splitted every 4-5 days at 50% - 80% confluency at 1:3 to 1:5 ratio.

### 4.2 Recommended Complete Medium

- DMEM/F12 with GlutaMAX I or L-Glutamine
- 10% FBS
- 1.0% Penicillin/Streptomycin

### 4.3 Antibiotics

- HEK Ca<sub>v</sub>3.2 clones were selected under 500 µg/mL G-418 antibiotic pressure.
- To cultivate HEK Ca<sub>v</sub>3.2 cells, a reduced antibiotic pressure (100 µg/mL) should be used.

Remark: The permanent application of antibiotic pressure has no effect on current density.

### 4.4 Thawing Cells

- Remove vial of cells from liquid nitrogen and thaw quickly at 37°C.
- Decontaminate outside of vial with 70% ethanol.
- Transfer cells to a T-25 culture flask containing 5 mL complete medium.
- Incubate cells at 37°C for 4-6 h to allow the cells to attach to the bottom of flask.
- Aspirate off the medium and replace with 5 mL complete medium & antibiotics.
- Antibiotics: 100 µg/ml G-418.
- Incubate cells and check them daily until 50% - 80% confluency is reached.

### 4.5 Splitting Cells

- When cells are 50% - 80% confluent remove complete medium.
- Wash cells once with 1x Trypsin/EDTA.
- Remove Trypsin/EDTA quickly and incubate cells for 3-5 min at room temperature.
- Detach cells, add complete medium and pipet up and down to break clumps of cells.
- Passage cells into new flask with complete medium and antibiotics at 1:3 to 1:5 ratio.
- Use remaining suspension for counting the cells.

#### 4.6 Freezing Medium

- Mix 0.9 mL fresh complete medium and 0.1 mL DMSO for every 1 mL freezing medium.
- Sterilize freezing medium by means of appropriate micro filter (0.1  $\mu\text{m}$  – 0.2  $\mu\text{m}$ ).

#### 4.7 Freezing Cells

- Prepare fresh freezing medium and keep it on ice.
- Cells should have 80% - 90% confluency prior to freezing.
- Remove the complete medium.
- Wash cells once with 1x Trypsin/EDTA.
- Remove Trypsin/EDTA quickly and incubate cells for 3-5 min at room temperature.
- Detach cells, add complete medium and pipet up and down to break clumps of cells.
- Pellet cells with centrifuge and carefully aspirate off medium.
- Resuspend cells at a density of approximately  $3.0 \times 10^6$  cells per mL with fresh freezing medium.
- Aliquot 0.5 mL of cell suspension into each cryovial.
- Overnight incubate cells in a styropor box at  $-80^{\circ}\text{C}$ .
- The next morning transfer cryovial in liquid nitrogen tank for long-term storage.

## 5 CA<sub>v</sub>3.2 SEQUENCE

### 5.1 Ca<sub>v</sub>3.2

Cloned cDNA sequence of Ca<sub>v</sub>3.2 (CACNA1H) subunit was error-free and is encoding for NP\_066921:

```
MTEGARAADAEVRVPLGAPPPGPAALV GASPE SPGAPGREAE RGSSELGVSPSESPA AERGAELGADEEQRVYPYAL
AATVFFCLGQTTRPRSWCLRLVCNPWF EHVSM LVI MLNCVTLGMFRPCEDVECGSERCNILEAFDAFIFAFFAVE
MVIKMAVALGLFGQKCYLGDTWNRLDFFIVVAGMMEYSLDGHNVSLSAIRTVRVLRPLRAINRVPSMRILVTL LLLD
TLPMLGNVLLLCFFVFFIFIGIVGVQLWAGLLRNRCFLDSAFVRN NNLTF LRPYYQTEEGEENPFICSSRRDNGMQ
KCSHIPGRREL RMPCTLGWEAYTQPQAEGVGAARNACINWNQYYNVCRSGDSNPHNGAINFDNIGYAWIAIFQVI
TLEGWVDIMYYVMDAHSFYNFYIFILLIIVGSFFMINLCLVVIATQFSETKQRESQLMREQRARHLSNDSTLASF
SEPGSCYEELLKYVGHIFRKVKRRSLRLYARWQSRWRKKVDP SAVQGGPGHRQRRAGRHTASVHHLVYHHHHHHH
HHYHFSHGSPRRPGPEPGACDTRLVRAGAPPSPSPGRGPPDAESVHSIYHADCHIEGPQERARVAHAAATAAA
SLRLATGLGTMNYPTILPSGVGSGKGSTSPGPKGKWAGGPPGTGGHGPLSLNSPDPYEKIPHVVGEHGLGQAPGH
LSGLSVPCPLPSPAGTTLTCELKSCPYCTRALEDPEGELSGSESGSDGGRGVYEFTQDVRHGDRWDPTRPPRATD
TPGPGPGSPQRRRQQRAAPGEPGWMGRLVWTFSGKLRRIVDSKYFSRGIMMAILVNTLSMGVEYHEQPEELTNAL
EISNIVFTSMFALEM LKLLACGPLGIYIRNPYNI F DGIIVVISVWEIVGQADGGLSVLRTFRLLRVLKLVRF LPA
LRRQLVVLVKTMDNVATFCTLLMLFIFIFISILGMHLFGCKFSLKTD TGD T V PDRKNFDSL LWAIVTVFQIILTQED
WNVVLYNGMASTSSWAALYFVALMTFGNYVLFNLLVA I LVEGFQAEGDANRSDTDEDKTSVHF EEDFHKLRELQT
TELKMCSLAVTPNGHLEGRGSLSPPLIMCTAATPMP TP KSSPFLDAAPSLPDSRRGSSSSSGDPPLGDQKPPASLR
SSPCAPWPGSPGAWSSRRSSWSSSLGRAPSLKRRGQCGERESLLSGEGKGSTDDEAEDGRAAPGPRATPLRRAESLD
PRPLRPAALPPTKCRDRDQVVALPSDFFLRIDSHREDAAE LDDSD SEDSCCLRLHKVLEPYKQWCRSREAWALY
LFSPQNRFRVSCQKVI THKMF DHVVLVFI FLNCVTIALERPDIDPGSTERVFLSVSNYIFTAIFVAEMMVKVVAL
GLLSGEHAYLQSSWNLLDGLLVLVSLVDIVVAMASAGGAKILGVLRLRLRLTLRPLRVISRAPGLKLVVETLIS
SLRPIGNIVLICCAFFIIFGILGVQLFKGKFYYCEGPDTRNISTKAQCRAAHYRWRRKYNFDNLGQALMSLFVL
SSKDGWVNIMYDGLDAVGVDQQP VQNHNPWMLLYFISFL LIVSFFVLNMFVGVVVENFHKCRQHQAEEARRREE
KRLRRLERRRRSTFPSPEAQRPPYYADYSPTRRSIHS LCTSHYLDLFI TFIICVNVITMSMEHYNQPKSLDEALK
YCNVYFTIVFVFEAALKLVAFGFRRFFKDRWNQLDLAIVLLSLMGITLLEEIEMSAALPINPTIIRIMRVLRIARV
LKLLKMATGMRALLDTVVQALPQVGNLGLLFMLLFFIYAALGVELFGRLECESDNPCEGLSRHATFSNFGMAFLT
LFRVSTGDNWNNGIMKDTLRECSREDKHCLSYLPALSPVYFVTFVLVAQFVLVNVVVAVLMKHLEESNKEAREDAE
LDAEIELEMAQGPSARRVDADRPPLPQESPGARDAPNLVARKVSVSRMLS L PND SYMFRPVVPASAPHRPLQE
VEMETYGAGTPLGSVASVHSPPAESCASLQIPLAVSSPARSGEPLHALSPRG TARSPSLSRLLCRQEAVHTDSLE
GKIDSPRDTLDPAEPGEKTPVRPVTQGGSLQSPPRSPPASVTRKHTFGQRCVSSRPAAPGGEEAEASDPADEE
VSHITSSACPWQPTAEPHGPEASPVAGGERDLRRLYSVDAQGF LDKPGRADQWRPSAELGSGEPGEAKAWGPEA
EPALGARRKKKMSPPCISVEPPAEDEGSARPSAAEGGSTTLRRRTPSCEATPHRDSLEPTEGSGAGGDPAAKGER
WGQASCRAEHLTVPSFAFEPLDLGVPSGDPFLDGSHSVTPESRASSSGAIVPLEPPESEPPMPVGDPEKRRGLY
LTVPQCPEKPGSPSATPAPGGGADDPV
```

## 6 CONTACT INFORMATION

### 6.1 Contact Address for Technical Support & Ordering Information

- B'SYS GmbH  
Technology Center Witterswil  
Benkenstrasse 254  
4108 Witterswil  
Switzerland

Tel: +41 61 721 77 44

Fax: +41 61 721 77 41

Email: [info@bsys.ch](mailto:info@bsys.ch)

Web: [www.bsys.ch](http://www.bsys.ch)